Piper reiterates Overweight on Crispr after ViaCyte collaboration

Piper Jaffray analyst Edward Tenthoff reiterates an Overweight rating on Crispr Therapeutics with a $67 price target after the company announced a collaboration with ViaCyte. ViaCyte is developing the stem cell therapy for insulin deficiency, but is currently limited by host rejection, Tenthoff tells investors in a research note. He points out that Crispr will develop gene-edited immuno-evasive properties into the cells, a potentially curative therapy. The analyst believes the collaboration leverages Crispr’s gene-editing in diabetes.
https://thefly.com/landingPageNews.php?id=2791495